Archived Policies - Prescription Drugs

Human Fibrinogen Concentrate (RiaSTAP)


Effective Date:01-01-2015

End Date:03-31-2016


Medical policies are a set of written guidelines that support current standards of practice. They are based on current peer-reviewed scientific literature. A requested therapy must be proven effective for the relevant diagnosis or procedure. For drug therapy, the proposed dose, frequency and duration of therapy must be consistent with recommendations in at least one authoritative source. This medical policy is supported by FDA-approved labeling and nationally recognized authoritative references. These references include, but are not limited to:  MCG care guidelines, Hayes, DrugDex (IIb level of evidence or higher), NCCN Guidelines (IIb level of evidence or higher), NCCN Compendia (IIb level of evidence or higher), professional society guidelines, and CMS coverage policy.

Human fibrinogen concentrate, pasteurized (HFCP) (RiaSTAP™) may be considered medically necessary for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (CFD) Factor I bleeding disorder, including afibrinogenemia and hypofibrinogenemia, when the following criteria are met:

Confirmed CFD by prothrombin time, partial thromboplastin time, thrombin clotting time, and reptilase time; AND

Failed response to substitution with a cryoprecipitate or substitution with fresh frozen plasma.

All other use of human fibrinogen concentrate (RiaSTAP™) is considered experimental, investigational and/or unproven, including but not limited to dysfibrinogenemia.


Fibrinogen deficiency affects only 150 to 300 people in the United States and is usually diagnosed at birth when newborns bleed from their umbilical cord site. Individuals with congenital fibrinogen deficiency (CFD) are unable to make sufficient amounts of fibrinogen (also called Factor I), which is a protein that plays an important role in blood coagulation by helping to form blood clots and prevent bleeding. Fibrinogen is manufactured in the liver and circulates in the blood plasma in a normal concentration of 250-400 mg/dL. Symptoms of CFD include excessive bleeding following an injury; bruising; spontaneous bleeding; and bone, joint, and tissue hemorrhage, in addition to the excessive bleeding at the umbilical cord site. (1, 2)

On January 16, 2009, the U.S. Food and Drug Administration (FDA) approved human fibrinogen concentrate, pasteurized (HFCP) (RiaSTAP™), a concentrated form of human fibrinogen (coagulation Factor I), as an orphan drug for the treatment of bleeding in patients with a rare genetic defect known as CFD. As of 2014, the labeling has remained unchanged, since the initial FDA approval. (1)

HFCP, made from the pooled plasma of healthy human blood donors, is for patients who have no fibrinogen or abnormally low levels, known as afibrinogenemia. Additional HFCP is made for those patients, whose fibrinogen levels fall below 50 mg/dL, known as hypofibrinogenemia. The FDA approval label states HFCP is not indicated for those patients having dysfibrinogenemia, in which the patient may have normal fibrinogen levels, but defective fibrinogen function. (1)

Abnormal bleeding times are identified and compared to normal bleeding times via laboratory blood coagulation testing or blood clotting factor assays, which includes the following:

Prothrombin time (PT): normal range from 10- to 18-seconds,

Partial thromboplastin time (PTT) or activated PTT (aPTT): normal range from 22- to 37-seconds,

International Normalized Ratio (INR): normal range (without anticoagulant therapy): 1 and normal range (with anticoagulant therapy): 2-3,

Thrombin clotting time (TCT, TT): < 21-seconds, and

Reptilase time (RT): < 23-seconds.

Additional testing may be completed to evaluate all aspects of a blood clotting disorder.

An orphan drug is defined in the 1984 amendments of the Orphan Drug Act as "a drug intended to treat a condition affecting fewer than 200,000 persons in the United States or will not recover development cost, plus a reasonable profit, within seven years following FDA approval. The Orphan Drug Act was signed into law on January 4, 1983."

HFCP is administered intravenously, with dosages based upon measured fibrinogen levels. Per the FDA label, a target fibrinogen level of 100 mg/dL should be maintained until hemostasis is obtained. (1)

To date, there are no other concentrated fibrinogen products available in the United States. HFCP is manufactured by CSL Behring GmbH, Marburg, Germany and distributed by CSL Behring LLC, Kankakee, Illinois. (1)


The FDA orphan product designation was based upon a study of 15 patients with afibrinogenemia who achieved the target level of fibrinogen expected to prevent bleeding after they received 70 milligrams/kilograms of the drug. In addition, plasma from 14 of the 15 patients showed increased maximum clot firmness, a surrogate marker likely to predict clinical benefit. (1)

This was a phase II multinational, multicenter (ten centers in the United States and Italy), prospective, open-label, and uncontrolled design clinical trial, conducted in subjects with CFD manifested as afibrinogenemia, in a non-bleeding state. Of the 15 subjects, ten were males, with 11 in an age range of 16 to <65 years and the balance between 8 and 14 years. Plasma fibrinogen activity and antigen screening had to be undetectable (<20 mg/dL). Human fibrinogen concentrate, pasteurized (HFCP) was administered as a single intravenous infusion of 70 milligram/kilogram body weight. Blood samples were drawn at pre-dose and at 0.5, 1, 2, 4, 8, 24, 96, 144, 216, and 312 hours post-dosing. Fourteen patient’s laboratory results were evaluated (one subject’s plasma samples thawed during transport). The pharmacokinetics of HFCP, in terms of plasma fibrinogen activity and antigen screening, indicate that HFCP has a long half-life and is slow clearance drug. The results indicated no difference between females and males. In children younger than 16 years, the half-life and clearance of HFCP were 11% shorter and 32% faster than in adults. However, due to the small study size of children younger than 16 years, it is difficult to make any outright conclusion. (2, 3)

In 2009, Beven (4) stated dysfibrinogenemia is characterized by functional abnormalities of fibrinogen, which may be asymptomatic (in 50% of cases), or cause bleeding (25%) or thrombosis (25%). Replacement of the deficient or abnormal fibrinogen with frozen plasma, cryoprecipitate, or fibrinogen concentrate has been found to be effective in practice in treating hemostatic complications related to congenital fibrinogen disorders. Although cryoprecipitate is the most commonly used replacement material, pathogen-reduced fibrinogen concentrates have several advantages, most importantly a lower potential risk of viral transmission and standardized fibrinogen content allowing accurate dosing. They also avoid transfusing unwanted clotting factors, platelet micro particles and immunoglobulins, and can be administered rapidly without thawing. The use of fibrinogen concentrate to treat congenital fibrinogen disorders is strongly supported in principle and increasingly by practical experience and evidence.

Fibrinogen is suggested to play a significant role in managing major bleeding. However, clinical evidence regarding the effect of fibrinogen concentrate (derived from human plasma) on transfusion is limited. In 2013, Rahe-Meyer et al. (5) assessed whether fibrinogen concentrate can reduce the need for blood transfusion when given as an intraoperative, targeted, first-line hemostatic therapy in bleeding patients undergoing aortic replacement surgery. A randomized, single-center, prospective, placebo-controlled, double-blind study in patients 18 years of age or older undergoing elective thoracic or thoracoabdominal aortic replacement surgery involving cardiopulmonary bypass was assessed. Patients were randomized to fibrinogen concentrate or placebo, administered intraoperatively. Study medication was given if patients had clinically relevant coagulopathic bleeding immediately after removal from cardiopulmonary bypass and completion of surgical hemostasis. Dosing was individualized using the fibrin-based thromboelastometry test. If bleeding continued, a standardized transfusion protocol was followed. Twenty-nine patients in the fibrinogen concentrate group and 32 patients in the placebo group were eligible for the efficacy analysis. During the first 24 hours after the administration of study medication, patients in the fibrinogen concentrate group received fewer allogeneic blood components than did patients in the placebo group (median, 2 vs. 13 U; P < 0.001; primary endpoint). Total avoidance of transfusion was achieved in 13 (45%) of 29 patients in the fibrinogen concentrate group, whereas 32 (100%) of 32 patients in the placebo group received transfusion (P < 0.001). There was no observed safety concern with using fibrinogen concentrate during aortic surgery. Hemostatic therapy with fibrinogen concentrate in patients undergoing aortic surgery significantly reduced the transfusion of allogeneic blood products. The study concluded that larger multicenter studies are necessary to confirm the role of fibrinogen concentrate in the management of perioperative bleeding in patients with life-threatening coagulopathy.

In 2014, Tanaka and colleagues (6) published a study compared hematologic and transfusion profiles between first-line acquired fibrinogen (FIB) replacement and platelet transfusion in post-cardiac surgical bleeding in a prospective, randomized, open-label study. Twenty adult patients who underwent valve replacement or repair and fulfilled a preset visual bleeding scale were randomized to 4 g of FIB or 1 unit of apheresis platelets. Primary endpoints included hemostatic condition in the surgical field and 24-hour hemostatic product usage. Hematologic data, clinical outcome, and safety data were collected up to the 28th day postoperative visit. In patients who received the first-line FIB concentrate (n = 10), the visual bleeding scale improved after intervention, and the incidence of PLT transfusion and total plasma donor exposure were lower compared to the PLT group (n = 10). Postintervention FIB level was statistically higher (209 mg/dL vs. 165 mg/dL) in the FIB group than in the PLT group, but PLT count and prothrombin were lower. There were no statistical differences in the postoperative blood loss and red blood cell transfusion between two groups. The preliminary data concluded that primary FIB replacement may potentially reduce the incidence of Platelet transfusion and the number of donor exposures. Plasma FIB level of 200 mg/dL is attainable with a single dose of 4 g, and this level seems to mitigate bleeding despite moderately decreased thrombin generation. It concluded, A

large prospective randomized study is warranted to examine the efficacy and safety of FIB therapy in high-risk cardiac surgical patients.


There are studies that evaluate the off label use fibrinogen concentrate. A 2013 Cochrane review (7) in bleeding patients concluded that while fibrinogen concentrate may reduce the number of transfusions required, the studies are low quality and underpowered to determine mortality, benefit or harm.

A current search of peer reviewed literature through October 31, 2014 identified small studies that evaluate the off label use of fibrinogen concentrate. Due to the lack of evidence that clinical outcomes are improved, off label use of fibrinogen concentrate is considered experimental, investigational and/or unproven.


Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.



Disclaimer for coding information on Medical Policies

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

The presence or absence of procedure, service, supply, device or diagnosis codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. Only the written coverage position in a medical policy should be used for such determinations.

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member’s benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.


The following codes may be applicable to this Medical policy and may not be all inclusive.

CPT Codes




ICD-9 Diagnosis Codes

Refer to the ICD-9-CM manual

ICD-9 Procedure Codes


ICD-10 Diagnosis Codes

Refer to the ICD-10-CM manual

ICD-10 Procedure Codes


Medicare Coverage:

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <>.


1. FDA – RiaSTAP (human fibrinogen concentrate, pasteurized) – Product Information, Label, Approval Letter, News Release. Food and Drug Administration (2009 January 16). Available at <> (accessed 2014 November 25).

2. Kreuz, W., Meili, E., et al. Efficacy and tolerability of a pasteurized human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfusion and Apheresis Science (2005 June); 32(3):247-53.

3. Negrier, C., Rothschild, C., et al. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. Journal of Thrombosis and Haemostatis (2008 September) 6(9); 1494-9.

4. Bevan DH. Cryoprecipitate: No longer the best therapeutic choice in congenital fibrinogen disorders. Thrombosis Research 2009; 124 Suppl 2:S12-S16.

5. Rahe-Meyer N1 et al., Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology (2013 May); 118(5):1244

6. Tanaka KA et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion (2014 January); 54(1):109-18.

7. Wikkelso et al., Fibrinogen concentrate in bleeding patients. Cochrane Database system Review (2013 August); CD008864.

Policy History:

Date Reason
1/1/2015 Document updated with literature review. Coverage unchanged.
8/1/2012 Document updated with literature review. Coverage unchanged.
1/1/2010 New medical document. Human Fibrinogen Concentrate (RaiSTAP ™) may be considered medically necessary when criteria are met for treatment of Factor I bleeding disorder (congenital fibrinogenemia).

Archived Document(s):

Title:Effective Date:End Date:
Human Fibrinogen Concentrate (RiaSTAP)04-15-201709-14-2018
Human Fibrinogen Concentrate (RiaSTAP)04-01-201604-14-2017
Human Fibrinogen Concentrate (RiaSTAP)01-01-201503-31-2016
Human Fibrinogen Concentrate (RiaSTAP)08-01-201212-31-2014
Human Fibrinogen Concentrate (RiaSTAP)01-01-201007-31-2012
Back to Top